Shenzhen Yuanxing

Shenzhen Yuanxing Gene-tech is a leading Chinese biotechnology company specializing in gene therapy and viral vector manufacturing. Founded in 2000 and headquartered in Shenzhen, the company has established a comprehensive platform for the development and production of adenovirus, adeno-associated virus (AAV), and lentivirus vectors. It is widely recognized for its pioneering role in the commercialization of Gendicine, the world's first approved gene therapy for head and neck cancer. In addition to its internal pipeline focused on oncology, the company serves as a major Contract Development and Manufacturing Organization (CDMO), supporting global biopharma partners with GMP-compliant production services. As a subsidiary of the Joincare Pharmaceutical Group, Shenzhen Yuanxing Gene-tech leverages extensive industrial resources to advance the field of genetic medicine.